To determine whether c-Myc and Mcl-1 downregulation is caused by GSK-3β activation, Ba/F3-ITD and MV4-11 cells and FLT3-ITD AML patient blasts were treated with gilteritinib and AZD1208 in the presence and absence of the GSK-3β inhibitor TG-C 24, and c-Myc and Mcl-1 expression was measured by immunoblotting at serial timepoints. The gene discussed is MYC; the disease is acute myeloid leukemia.